CCR3 and metabolic dysfunction-associated steatohepatitis: In liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), CCL24 and CCR3 are upregulated, and CCL24 blockade with the neutralizing antibody CM-101 reduced liver damage and fibrosis in preclinical models [6,10].